.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Deloitte
Farmers Insurance
Merck
Colorcon
Boehringer Ingelheim
Johnson and Johnson
Dow
Julphar
Harvard Business School

Generated: September 20, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 8,485,180 protect, and when does it expire?


Patent ► Subscribe protects AFREZZA and is included in one NDA.

This patent has two hundred and thirty-four patent family members in twenty-three countries.

Summary for Patent: ► Subscribe

Title:Dry powder drug delivery system
Abstract: A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of endocrine disease, for example, diabetes and/or obesity.
Inventor(s): Smutney; Chad C. (Watertown, CT), Adamo; Benoit (Mount Kisco, NY), Polidoro; John M. (Coventry, CT), Kinsey; P. Spencer (Sandy Hook, CT), Overfield; Dennis (Fairfield, CT), Sahi; Carl R. (Coventry, CT), Billings; Christine (Danbury, CT), Marino; Mark T. (Danbury, CT)
Assignee: MannKind Corporation (Valencia, CA)
Application Number:12/717,884
Patent Claim Types:
see list of patent claims
Formulation; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Mannkind
AFREZZA
insulin recombinant human
POWDER;INHALATION022472-001Jun 27, 2014RXYesNo► Subscribe► SubscribeY
Mannkind
AFREZZA
insulin recombinant human
POWDER;INHALATION022472-002Jun 27, 2014RXYesYes► Subscribe► SubscribeY
Mannkind
AFREZZA
insulin recombinant human
POWDER;INHALATION022472-003Apr 17, 2015RXYesNo► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,912,193Dry powder inhaler and system for drug delivery► Subscribe
9,339,615Dry powder inhaler and system for drug delivery► Subscribe
8,921,311Method for treating hyperglycemia► Subscribe
9,192,675Dry powder inhaler and system for drug delivery► Subscribe
7,799,344Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents► Subscribe
8,420,604Method of drug formulation of compositions comprising crystalline microparticle surfaces► Subscribe
9,511,198Dry powder inhaler and system for drug delivery► Subscribe
9,358,352Dry powder drug delivery system and methods► Subscribe
9,446,001Increasing drug affinity for crystalline microparticle surfaces► Subscribe
8,377,869Method of preventing adverse effects by GLP-1► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan201540332► Subscribe
Taiwan201002378► Subscribe
TaiwanI528982► Subscribe
Taiwan201036656► Subscribe
Slovenia2379100► Subscribe
Singapore10201507038V► Subscribe
Singapore10201507036T► Subscribe
Russian Federation2014152320► Subscribe
Russian Federation2012146344► Subscribe
Russian Federation2012136221► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Covington
AstraZeneca
Chubb
Accenture
Mallinckrodt
Colorcon
Queensland Health
McKinsey
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot